Molecular and cellular mechanisms by which diabetes mellitus promotes the development of atherosclerosis

Biochemistry of Atherosclerosis

Volumn , Issue , 2006, Pages 284-304

  Werstuck, Geoff H ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

accelerated atherosclerosis; animal models; diabetes mellitus; hyperglycemia; molecular mechanisms

Indexed keywords

EID: 84900650983     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-36279-3_13     Document Type: Chapter

References (117)

1. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414-1431, 1998.
2. Zimmet P, Alberti KGMM, Shaw J: Global and societal implications of the diabetes epidemic. Nature 414: 782-788, 2001.
3. Kannel WB, McGee DL: Diabetes and cardiovascular disease. The Framingham study. JAMA 241: 2035-2038, 1979.
4. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234, 1998.
5. Resnick HE, Howard BV: Diabetes and cardiovascular disease. Annu Rev Med 53: 345-367, 2002.
6. Canadian Diabetes Association Clinical Practice Guidelines Experts Committee: Definition, classification and diagnosis of diabetes and other dysg-lycemic categories. Canadian J Diabetes 27: S7-S9, 2003.
7. Tisch R, McDevitt H: Insulin dependent diabetes mellitus. Cell 85: 291-297, 1906.
8. Mathis D, Vence L, Benoist C: β cell death during progression to diabetes. Nature 414: 792-798, 1998.
9. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Invest 106: 453-458, 2000.
10. Bell GI, Polonsky KS: Diabetes mellitus and genetically programmed defect in β-cell function. Nature 414: 788-791, 2001.
11. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-medial thickness in type 1 diabetes mellitus. New Engl J Med 348: 2294-2303, 2003.
12. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKSPDS 33). Lancet 352: 837-853, 1998.
13. Haffner SM: The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease. Endocrine Rev 19: 583-592, 1998.
14. Standl E, Balletshofer B, Dahl B, Weichenhain B, Steigler H, Hormann A, Holl R: Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39: 1540-1545, 1996.
15. Lehto S, Ronnemaa T, Haffner SM, Pyorala K, Kallio V, Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46: 1354-1359, 1997.
16. Santilli SM, Fiegel VD, Aldridge DE, Knighton DR: The effect of diabetes on the proliferation of aortic endothelial cells. Ann Vasc Surg 6: 503-510, 1992.
17. Huvers FC, De Leeuw PW, Houben AJ, De Haan CH, Hamulyak K, Schouten H, Wolffenbuttel BH, Schaper NC: Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes 48: 1300-1307, 1999.
18. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A: Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes 52: 2795-2804, 2003.
19. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S; Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348: 2294-2303, 2003.
20. Lawes CM, Parag V, Bennett DA, Suh I, Lam TH, Whitlock G, Barzi F, Woodward M; Asia Pacific Cohort Studies Collaboration: Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 27: 2836-2842, 2004.
21. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109: 433-438, 2004.
22. World Health Organization: Obesity: preventing and managing the global epidemic. (WHO Technical Report Series, No. 894), 2003.
23. Grundy SM: Metabolic complications of obesity. Endocrine 13: 155-165, 2000.
24. Kunjathoor VV, Wilson D, LeBoeuf RC: Increased atherosclerosis in streptozo-tocin-induced diabetic mice. J Clin Invest 97: 1767-1773, 1996.
25. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4: 1025-1031, 1998.
26. Fazio S, Linton MF: Mouse models of hyperlipidemia and atherosclerosis. Front Biosci 6: D515-D525, 2001.
27. Rees DA, Alcolado JC: Animal models of diabetes mellitus. Diabet Med 22: 359-370, 2005.
28. Breslow JL: Mouse models of atherosclerosis. Science 272: 685-688, 1996.
29. Szkudelski T: The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res 50: 537-546, 2001.
30. - formation. Biochem Pharmacol 38: 271-277, 1989.
31. Schnedl WJ, Ferber S, Johnson JH, Newgard CB: STZ transport and cytotoxi-city. Specific enhancement in GLUT2-expressing cells. Diabetes 43: 1326-1333, 1994.
32. Renard CB, Kramer F, Johansson F, Lamharzi N, Tannock LR, Herrath MG, Chait A, Bornfeldt KE: Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 114: 659-668, 2004.
33. Reaven P, Merat S, Casandra F, Sutphin M, Palinski W: Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation end-products in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 17: 2250-2256, 1997.
34. Kako Y, Huang L-S, Yang J, Katopodis T, Ramakrishnan R, Goldberg IJ: Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice: effects on lipoproteins and atherosclerosis. J Lipid Res 40: 2185-2194, 1999.
35. Goldberg IJ, Isaacs A, Sehayek E, Breslow JL, Huang L-S: Effects of streptozo-tocin-induced diabetes in apolipoprotein AI deficient mice. Atherosclerosis 172: 47-53, 2004.
36. Hasty AH, Shimano H, Osuga J, Namatame I, Takahashi A, Yahagi N, Perrey S, Iizuka Y, Tamura Y, Amemiya-Kudo M, Yoshikawa T, Okazaki H, Ohashi K, Harada K, Matsuzaka T, Sone H, Gotoda T, Nagai R, Ishibashi S, Yamada N: Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low-density lipoprotein receptor. J Biol Chem 276: 37402-37408, 2001.
37. Ross R: Atherosclerosis-an inflammatory disease. New Engl J Med 340: 115-126, 1999.
38. Lusis AJ: Atherosclerosis. Nature 407: 233-241, 2000.
39. Drielsma RF, Burnett JR, Gray-Weale AC, Byrne K, Lusby RJ: Carotid artery disease: the influence of diabetes mellitus. J Cardiovasc Surg (Torino) 29: 692-696, 1988.
40. Silva JA, Escobar A, Collins TJ, Ramee SR, White CJ: Unstable angina. A comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 92: 1731-1736, 1995.
41. Srivastava SK, Ansari NH, Hair GA, Jaspan J, Rao MB, Das B: Hyperglycemia-induced activation of human erythrocyte aldose reductase and alterations in kinetic properties. Biochim Biophys Acta 870: 302-311, 1986.
42. Chung SS, Ho EC, Lam KS, Chung SK: Contribution of polyol pathway to diabetes-induced oxidative stress. J Am Soc Nephrol 14: S233-S236, 2003.
43. Greene DA, Arezzo JC, Brown MB, the Zenarestat Study Group: Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 53: 580-591, 1999.
44. Sorbinil Retinopathy Trial Research Group: The Sorbinil Retinopathy Trial: Neuropathy results. Neurology 43: 1141-1149, 1993.
45. Engerman RL, Kern TS, Larson ME: Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosaemia in dogs. Diabetologia 37: 141-144, 1994.
46. Brown MJ, Bird SJ, Watling S, Kaleta H, Hayes L, Eckert S, Foyt HL; Zenarest study: Natural progression of diabetic peripheral neuropathy in the Zenarestat study population. Diabetes Care 27: 1153-1159, 2004.
47. Marshall S, Bacote V, Traxinger RR: Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. J Biol Chem 266: 4706-4712, 1991.
48. Nerlich AG, Sauer U, Kolm-Litty V, Wagner E, Koch M, Schleicher ED: Expression of glutamine:fructose-6-phosphate amidotransferase in human tissues: evidence for high variability and distinct regulation in diabetes. Diabetes 47: 170-178, 1998.
49. Herbert LF, Daniels MC, Zhou J, Crook ED, Turner RL, Simmons ST, Neidigh JL, Zhu JS, Baron AD, McClain DA: Overexpression of glutamine: fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Invest 98: 930-936, 1996.
50. Lui K, Paterson AJ, Chin E, Kudlow JE: Glucose stimulates protein modification by O-linked GlcNAc in pancreatic beta cells: linkage of O-linked GlcNAc to beta cell death. Proc Natl Acad Sci USA 14: 2820-2825, 2000.
51. Stender S, Astrup P: Glucosamine and experimental atherosclerosis. Increased wet weight and changed composition of cholesterol fatty acids in aorta of rabbits fed a cholesterol-enriched diet with added glucosamine. Atherosclerosis 26: 205-213, 1977.
52. Han I, Kudlow JE: Reduced O glycosylation of SP1 is associated with increased proteasome susceptibility. Mol Cell Biol 17: 2550-2558, 1997.
53. Han I, Oh E, Kudlow JE: Responsiveness of the state of O-linked N-acetyl-glucosamine modification of nuclear pore protein p62 to the extracellular glucose concentration. Biochem J 350: 109-114, 2000.
54. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M: Hyperglycemia inhibits nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108: 1341-1348, 2001.
55. Hawkins M, Angelov I, Liu R, Barzilai N, Rossetti L: The tissue concentration of UDP-N-acetylglucosamine modulates the stimulatory effect of insulin on skeletal muscle glucose uptake. J Biol Chem 272: 4889-4895, 1997.
56. Ross SA, Chen X, Hope HR, Sun S, McMahon EG, Broschat K, Gulve EA: Development and comparison of two 3T3-L1 adipocyte models of insulin resistance: increased glucose flux vs glucosamine treatment. Biochem Biophys Res Commun 273: 1033-1041, 2000.
57. James LR, Fantus IG, Goldberg H, Ly H, Scholey JW: Overexpression of GFAT activates PAI-1 promoter in mesangial cells. Am J Physiol Renal Physiol 279: F718-F727, 2000.
58. Du X-L, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M: Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97: 12222-12226, 2000.
59. Morin MJ, Porter CW, McKernan P, Bernacki RJ: The biochemical and ultra-structural effects of tunicamycin and D-glucosamine in L1210 leukemic cells. J Cell Physiol 114: 162-172, 1983.
60. Lin H, Masso-Welsh P, Di Y, Cai J, Shen J, Subjeck JR: The 170-kDa glucose-regulated stress protein is an endoplasmic reticulum protein that binds immunoglobulin. Mol Biol Cell 4: 1109-1119, 1993.
61. Miskovic D, Salter-Cid L, Ohan N, Flajnik M, Heikkila JJ: Isolation and characterization of a cDNA encoding a Xenopus immunoglobulin binding protein, BiP (GRP78). Comp Biochem Physiol 116: 227-234, 1997.
62. Kim AJ, Shi YY, Austin RC, Werstuck GH: Valproate protects cells from endo-plasmic reticulum stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase 3. J Cell Sci 118: 89-99, 2005.
63. Helenius A: How-linked oligosaccharides effect protein folding in the endoplas-mic reticulum. Mol Biol Cell 5: 253-265, 1994.
64. Travers KJ, Patil CK, Wodicka L, Lockhart DJ, Weissman JS, Walter P: Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation. Cell 101: 249-258, 2000.
65. Friedlander R, Jarosch E, Urban J, Volkwein C, Sommer T: A regulatory link between ER-associated protein degradation and the unfolded-protein response. Nat Cell Biol 2: 379-384, 2000.
66. Pahl HL: Signal transduction from the endoplasmic reticulum to the cell nucleus. Physiol Rev 79: 683-701, 1999.
67. Kaufman RJ: Stress signalling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev 13: 1211-1233, 1999.
68. Harding HP, Zhang Y, Ron D: Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397: 271-274, 1999.
69. Cox JS, Shamu CE, Walter P: Translational induction of genes encoding endo-plasmic reticulum resident proteins requires a transmembrane protein kinase. Cell 73: 1197-1206, 1993.
70. Wang X-Z, Harding HP, Zhang Y, Jolicoeur EM, Kuroda M, Ron D: Cloning of mammalian Ire1 reveals diversity in the ER stress response. EMBO J 17: 5708-5717, 1998.
71. Yoshida H, Haze K, Yanagi H, Yura T, Mori K: Identification of the cis-acting endoplasmic reticulum stress response element responsible for the transcrip-tional induction of mammalian glucose-regulated proteins. J Biol Chem 273: 33741-33749, 1998.
72. Zinszner H, Kuroda M, Wang X-Z, Batchvarova N, Lightfoot RT, Remotti H, Stevens JL, Ron D: CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 12: 982-995, 1998.
73. Werstuck GH, Lentz SR, Dayal S, Shi Y, Hossain GS, Sood SK, Krisans SK, Austin RC: Homocysteine causes dysregulation of the cholesterol and fatty acid biosynthesis pathways. J Clin Invest 107: 1263-1273, 2001.
74. Lee JN, Ye J: Proteolytic activation of SREBP induced by cellular stress through the depletion of Insig-1. J Biol Chem 279: 45257-45265, 2004.
75. Jiang H-Y, Wek SA, McGrath BC, Scheuner D, Kaufman RJ, Cavener DR, Wek RC: Phosphorylation of the alpha subunit of eukaryotic initiation factor 2 is required for activation of NF-kappaB in response to diverse cellular stresses. Mol Cell Biol 23: 5651-5663, 2003.
76. Hossain GS, van Thienen JV, Werstuck GH, Zhou J, Sood SK, Dickhout JG, de Koning AB, Tang D, Wu D, Falk E, Poddar R, Jacobsen DW Zhang K, Kaufman RJ, Austin RC: TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem 278: 30317-30327, 2003.
77. Özcan U, Cao Q, Yilmaz E, Lee A-H, Iwakoshi NN, Özdelen E, Tuncman G, Görgun C, Glimcher LH, Hotamisligil GS: Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306: 457-461, 2004.
78. Li Y, Schwabe RF, Devries-Seimon T, Yao PM, Gerbod-Giannone MC, Tall AR, Davis RJ, Flavell R, Brenner DA, Tabas I: Free cholesterol-loaded macrophages are an abundant source of TNF-alpha and IL-6. Model of NF-kappa B-and MAP kinase-dependent inflammation in advanced atherosclerosis. J Biol Chem 280: 21763-21772, 2005.
79. Tesfamariam B, Brown ML, Cohen RA: Elevated glucose impairs endothelium-dependent relaxation by activating protein kinase C. J Clin Invest 87: 1643-1648, 1991.
80. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H: High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49: 1939-1945, 2000.
81. Omi H, Okayama N, Shimizu M, Okouchi M, Ito S, Fukutomi T, Itoh M: Participation of high glucose concentrations in neutrophil adhesion and surface expression of adhesion molecules on cultured human endothelial cells: effect of antidiabetic medicines. J Diabetes Complications 16: 201-208, 2002.
82. Yang CM, Chien CS, Hsiao LD, Pan SL, Wang CC, Chiu CT, Lin CC: Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway. Br J Pharmacol 132: 1531-1541, 2001.
83. Greene EL, Lu G, Zhang D, Egan BM: Signaling events mediating the additive effects of oleic acid and angiotensin II on vascular smooth muscle cell migration. Hypertension 37: 308-312, 2001.
84. Li L, Sawamura T, Renier G: Glucose enhances human macrophage LOX-1 expression: role for LOX-1 in glucose-induced macrophage foam cell formation. Circ Res 94: 892-901, 2004.
85. Inoguchi T, Xia P, Kunisaki M, Higashi S, Feener EP, King GL: Insulin's effect on protein kinase C and diacylglycerol induced by diabetes and glucose in vascular tissues. Am J Physiol 267: E369-E379, 1994.
86. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272: 728-731, 1996.
87. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW: Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34: 3702-3709, 1995.
88. Degenhardt TP, Thorpe SR, Baynes JW: Chemical modification of proteins by methylglyoxal. Cell Mol Biol 44: 1139-1145, 1998.
89. Ulrich P, Cerami A: Protein glycation, diabetes, and aging. Recent Prog Horm Res 56: 1-21, 2001.
90. Sgarbieri VC, Amaya J, Tanaka M, Chichester CO: Nutritional consequences of the Maillard reaction. Amino acid availability from fructose-leucine and fruc-tose-tryptophan in the rat. J Nutr 103: 657-663, 1973.
91. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H: Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836-842, 1991.
92. Koschinsky T, He C-J, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy Proc Natl Acad Sci USA 94: 6474-6479, 1997.
93. Liu J, Masurekar MR, Vatner DE, Jyothirmayi GN, Regan TJ, Vatner SF, Meggs LG, Malhotra A: Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am J Physiol Heart Circ Physiol 285:H2587-H2591, 2003.
94. Tanaka S, Avigad G, Brodsky B, Eikenberry EF: Glycation induces expansion of the molecular packing of collagen. J Mol Biol 203: 495-505, 1988.
95. Haitoglou CS, Tsilibary EC, Brownlee M, Charonis AS: Altered cellular interactions between endothelial cells and nonenzymatically glucosylated lamin/type IV collagen. J Biol Chem 267: 12404-12407, 1992.
96. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glyca-tion end products of proteins. J Biol Chem 267: 14998-15004, 1992.
97. Li YM, Mitsuhashi T, Wojciechowicz D, Shimizu N, Li J, Stitt A, He C, Banerjee D, Vlassara H: Molecular identity and cellular distribution of advanced glyca-tion endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. Proc Natl Acad Sci USA 93: 11047-11052, 1997.
98. Smedsrod B, Melkko J, Araki N, Sano H, Horiuchi S: Advanced glycation end products are eliminated by scavenger-receptor-mediated endocytosis in hepatic sinusoidal Kupffer and endothelial cells. Biochem J 322: 567-573, 1997.
99. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, Ferran LJ Jr, Kohl B, Rao V, Kisiel W, Stern DM, Schmidt AM: Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 107: 675-683, 2001.
100. Lander HM, Taurus JM, Ogiste JS, Hori O, Moss RA, Schmidt AM: Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidative stress. J Biol Chem 272: 17810-17814, 1997.
101. Karachalias N, Babaei-Jadidi R, Ahmed N, Thornalley PJ: Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans 31: 1423-1425, 2003.
102. Flyvbjerg A, Denner L, Schrijvers BF, Tilton RG, Mogensen TH, Paludan SR, Rasch R: Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes 53: 166-172, 2004.
103. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G, Cooper ME: The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17: 1762-1764, 2003.
104. Meng J, Sakata N, Takebayashi S, Asano T, Futata T, Araki N, Horiuchi S: Advanced glycation end products of the Maillard reaction in aortic pepsin-insoluble and pepsin-soluble collagen from diabetic rats. Diabetes 45: 1037-1043, 1996.
105. Brett J, Schmidt AM, Yan SD, Zou YS, Weidman E, Pinsky D, Nowygrod R, Neeper M, Przysiecki C, Shaw A: Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 143: 1699-1712, 1993.
106. Forbes JM, Yee LT, Thallas V, Lassila M, Candido R, Jandeleit-Dahm KA, Thomas MC, Burns WC, Deemer EK, Thorpe SM, Cooper ME, Allen TJ: Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes 53: 1813-1823, 2004.
107. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4: 1025-1031, 1998.
108. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM: RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106: 2827-2835, 2002.
109. Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y: Central role of RAGE-dependent neointimal expansion in arterial restenosis. J Clin Invest 111: 959-972, 2003.
110. Williams ME: Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease. Curr Diab Rep 4: 441-446, 2004.
111. Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 11: 191-195, 2005.
112. Valencia JV, Mone M, Koehne C, Rediske J, Hughes TE: Binding of receptor for advanced glycation end products (RAGE) ligands is not sufficient to induce inflammatory signals: lack of activity of endotoxin-free albumin-derived advanced glycation end products. Diabetologia 47: 844-852, 2004.
113. Valencia JV, Zhang MM, Weetall M, Buxton FP, Hughes TE: Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. Diabetes 53: 743-751, 2004.
114. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000.
115. Lonn EM, Yusuf S, Dzavik V, Doris CI, Yi Q, Smith S, Moore-Cox A, Bosch J, Riley WA, Teo KK, for the SECURE Investigators: Effects of Ramipril and vitamin E on atherosclerosis. The study to evaluate cartotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 103: 919-925, 2001.
116. McQuillan BM, Hung J, Beilby JP, Nidorf M, Thompson PL: Antioxidant vitamins and the risk of carotid atherosclerosis. The Perth carotid ultrasound disease assessment study (CUDAS). J Am Coll Cardiol 38: 1788-1784, 2001.
117. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold JM, Ross C, Arnold A, Sleight P, Probstfield J, Dagenais GR, HOPE and HOPE-TOO Trial Investigators: Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293: 1338-1347, 2005.